Nearly One in Four Autoimmune Hepatitis Patients Also Has Another Autoimmune Disease, Study Finds
Autoimmune hepatitis, often abbreviated as AIH, is a chronic liver disease in which the immune system turns against the liver's own cells, causing persistent inflammation that can lead to scarring, cirrhosis, liver failure, and even liver cancer if left unmanaged. Like many autoimmune conditions, it is far more common in women than in men, with incidence rates roughly four times higher in females. It can appear at any age, and because its symptoms, such as fatigue, joint pain, jaundice, and abdominal discomfort, overlap with many other conditions, it is sometimes diagnosed only after significant liver damage has already occurred. Long-term treatment typically involves immunosuppressive medications, most often corticosteroids combined with azathioprine.
What clinicians and patients have long observed, but what has lacked robust data in certain populations, is that autoimmune hepatitis rarely travels alone. People with one autoimmune condition are at elevated risk of developing others, and AIH is no exception. A study published in the Journal of Clinical and Translational Hepatology in January 2026 and highlighted in an EurekAlert press release this April examined just how common this overlap is, and what it means for treatment. Researchers reviewed medical records for 371 Han Chinese patients diagnosed with AIH between March 2016 and October 2023 at a single center, making it one of the larger real-world datasets of its kind in this population.
The findings were notable. Nearly 24 percent of patients, specifically 89 out of 371, had at least one extrahepatic autoimmune disease alongside their AIH. The two most common coexisting conditions were Sjogren's syndrome, which affected 8.63 percent of the group, and autoimmune thyroid disease, affecting 8.36 percent. The vast majority of patients in the study were female, at 81.94 percent, with a median age of 52.5 years. Coexisting autoimmune diseases were most prevalent in type 1 AIH, the most common form, appearing in 27.06 percent of those patients, compared with 11.11 percent in antibody-negative AIH and zero percent in the rare type 2 form.
The research team also found that patients with extrahepatic autoimmune diseases had a distinct laboratory profile at diagnosis. They tended to have lower levels of alanine aminotransferase, a key marker of liver inflammation, but higher ratios of aspartate aminotransferase to alanine aminotransferase, suggesting a somewhat different pattern of liver injury. Antinuclear antibody positivity, a common marker in autoimmune conditions, was significantly more frequent in patients with coexisting autoimmune diseases and was identified as an independent risk factor for their occurrence, with an odds ratio of 2.2.
The treatment implications were also significant. After three months of standard therapy, patients with extrahepatic autoimmune diseases had a lower rate of complete biochemical response, meaning their liver enzyme levels were less likely to normalize, at 40 percent compared with 55.3 percent in those without coexisting autoimmune conditions. However, by six months and beyond, outcomes were comparable between the two groups, suggesting that the presence of additional autoimmune diseases slows the initial treatment response but does not compromise long-term control if therapy is continued and adjusted appropriately.
For patients and caregivers, this study is a useful reminder that autoimmune hepatitis does not exist in isolation. Symptoms like dry eyes, dry mouth, or thyroid abnormalities that develop alongside a liver diagnosis are worth reporting to a physician promptly. The authors recommend routine screening for extrahepatic autoimmune diseases as part of standard AIH clinical evaluation, as well as closer monitoring of treatment response in the early months for those who have overlapping conditions. Recognizing the full picture of a patient's autoimmune profile can help clinicians tailor therapy and set realistic expectations from the start.